"Sandoz Will be the Leading Biosimilar Drug Company in 2012, with Revenue of $308 Million" Predicts New Visiongain Report

A new report by Visiongain predicts that Sandoz will retain its position as the global leader in the biosimilar drugs market in 2012. In that year, its three follow-on biologics will achieve $308m in revenue. Combined revenue for the top three companies in …